A partir de June 9, 2020,
a U.S. patent (10/675,294) for a pharmaceutical composition for the tratamiento of daño corneal containing 8-oxo-2'-deoxyguanosine or a pharmaceutically acceptable salt thereof as an active ingredient
ha sido registró, and we are pleased to announce this achievement. Basándose en esto patent, RudaCure is simultaneously pursuing U.S. ensayo clínicos and preparing for its U.S. mercado entry.